Scientific Reports (Nov 2021)

Clinical and molecular characterization of a large cohort of childhood onset hereditary spastic paraplegias

  • Gabriela Marchisio Giordani,
  • Fabrício Diniz,
  • Helena Fussiger,
  • Carelis Gonzalez-Salazar,
  • Karina Carvalho Donis,
  • Fernando Freua,
  • Roberta Paiva Magalhães Ortega,
  • Julian Letícia de Freitas,
  • Orlando Graziani Povoas Barsottini,
  • Sergio Rosemberg,
  • Fernando Kok,
  • José Luiz Pedroso,
  • Marcondes Cavalcante França,
  • Jonas Alex Morales Saute

DOI
https://doi.org/10.1038/s41598-021-01635-2
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 9

Abstract

Read online

Abstract The present study aimed to characterize clinical and molecular data of a large cohort of subjects with childhood-onset hereditary spastic paraplegias (HSPs). A multicenter historical cohort was performed at five centers in Brazil, in which probands and affected relatives' data from consecutive families with childhood-onset HSP (onset < 12 years-old) were reviewed from 2011 to 2020. One hundred and six individuals (83 families) with suspicion of childhood-onset HSP were evaluated, being 68 (50 families) with solved genetic diagnosis, 6 (5 families) with candidate variants in HSP-related genes and 32 (28 families) with unsolved genetic diagnosis. The most common childhood-onset subtype was SPG4, 11/50 (22%) families with solved genetic diagnosis; followed by SPG3A, 8/50 (16%). Missense pathogenic variants in SPAST were found in 54.5% of probands, favoring the association of this type of variant to childhood-onset SPG4. Survival curves to major handicap and cross-sectional Spastic Paraplegia Rating Scale progressions confirmed the slow neurological deterioration in SPG4 and SPG3A. Most common complicating features and twenty variants not previously described in HSP-related genes were reported. These results are fundamental to understand the molecular and clinical epidemiology of childhood-onset HSP, which might help on differential diagnosis, patient care and guiding future collaborative trials for these rare diseases.